Pancreatic Cancer News and Research

RSS
Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.
ESMO releases revised set of clinical guidelines for cancer patient care

ESMO releases revised set of clinical guidelines for cancer patient care

Hope for ovarian cancer patients not responding to conventional chemotherapy

Hope for ovarian cancer patients not responding to conventional chemotherapy

Neogenix Oncology files patent application with USPTO for 16C3 antigen

Neogenix Oncology files patent application with USPTO for 16C3 antigen

Eli Lilly, Alnara sign definitive merger agreement

Eli Lilly, Alnara sign definitive merger agreement

Threshold Pharmaceuticals initiates Phase 2 clinical trial of TH-302 in patients with first line pancreatic cancer

Threshold Pharmaceuticals initiates Phase 2 clinical trial of TH-302 in patients with first line pancreatic cancer

Celgene signs definitive merger agreement to acquire Abraxis BioScience

Celgene signs definitive merger agreement to acquire Abraxis BioScience

Threshold Pharmaceuticals commences TH-302 Phase 1 clinical trial in patients with advanced leukemias

Threshold Pharmaceuticals commences TH-302 Phase 1 clinical trial in patients with advanced leukemias

People in Medicare's two-year disability waiting period continue to wait

People in Medicare's two-year disability waiting period continue to wait

Zeria reports positive results from Japanese Phase III study of Z-338 for functional dyspepsia

Zeria reports positive results from Japanese Phase III study of Z-338 for functional dyspepsia

Patent application for tumor specific NPC-1C Antigen filed by Neogenix Oncology

Patent application for tumor specific NPC-1C Antigen filed by Neogenix Oncology

Tikcro Technologies reports net income of $1.9 million for first-quarter 2010

Tikcro Technologies reports net income of $1.9 million for first-quarter 2010

New presentations on neuroendocrine tumors at ESMO 12th World Congress on Gastrointestinal Cancer

New presentations on neuroendocrine tumors at ESMO 12th World Congress on Gastrointestinal Cancer

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

Pancreatic Cancer Action Network hosts fourth annual Pancreatic Cancer Advocacy Day

Pancreatic Cancer Action Network hosts fourth annual Pancreatic Cancer Advocacy Day

ExonHit Therapeutics informs shareholders about Highmark's intention to discontinue coverage of PathFinderTG

ExonHit Therapeutics informs shareholders about Highmark's intention to discontinue coverage of PathFinderTG

Lantis Laser to merge with Perio-Imaging

Lantis Laser to merge with Perio-Imaging

New combination appears to be effective against cancer stem cells in pancreatic cancer

New combination appears to be effective against cancer stem cells in pancreatic cancer

Women who drink boiled coffee at lower risk of breast cancer

Women who drink boiled coffee at lower risk of breast cancer

FDA grants orphan drug designation for ICT-107

FDA grants orphan drug designation for ICT-107

NeoPharm first-quarter net loss decreases to $1.4 million

NeoPharm first-quarter net loss decreases to $1.4 million

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.